Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus
Status:
RECRUITING
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (Part 1), and the safety, tolerability and PD of multiple doses of ARO-INHBE in adult participants with obesity with and without type 2 diabetes mellitus receiving tirzepatide (Part 2).